A study of patients receiving a combination of two immunotherapy drugs approved for treating melanoma found such patients had a 52 percent five-year survival rate.
At a minimum follow-up of 60 months, the median overall survival was more than 60.0 months (median not reached) in the nivolumab-plus-ipilimumab group and 36.9 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.52; hazard ratio for death with nivolumab vs. ipilimumab, 0.63). Overall survival at 5 years was 52% in the nivolumab-plus-ipilimumab group and 44% in the nivolumab group, as compared with 26% in the ipilimumab group. No sustained deterioration of health-related quality of life was observed during or after treatment with nivolumab plus ipilimumab or with nivolumab alone. No new late toxic effects were noted.
Typically, the five year survival rate for stage 4 melanoma has been in the 15-20 percent range.
There are no differences between the October 20, 2019 @ 16:58:29 revision and the current revision. (Maybe only post meta information was changed.)